Key Highlights
- Diageo's FY2026 Volume decline of 0.4%, alongside an 11.5% US spirits sales drop, is consistent with structural Demand erosion, not solely distributor destocking.
- Independent research shows 44% of GLP-1 users report drinking less alcohol, with 82% sustaining that reduction even after stopping the medication.
- Guinness's double-digit UK growth and the wider RTD cocktail trend suggest Diageo's structural hedge lies in beer and convenience formats rather than traditional neat spirits.
Diageo's decision to cut nearly 2,000 jobs and launch a $1bn cost-savings programme under new chief executive Sir Dave Lewis has been framed largely as a response to a cyclical North American slowdown. But a closer examination of the forces weighing on global spirits demand — from the rapid uptake of GLP-1 weight-loss drugs to a documented decline in drinking among younger adults — suggests the world's largest spirits company may be confronting something more structural than a normal inventory cycle. That distinction matters enormously for investors: a cyclical downturn resolves itself once distributor destocking ends and consumer confidence recovers, while a structural shift in category demand requires a fundamentally different long-term strategy, regardless of how efficiently the underlying Business is run.
What Happened
Diageo's fiscal 2026 results, published alongside its Annual Report on 19 August 2026, showed North American net sales down 8.4% for the year and US spirits specifically down 11.5%, driven substantially by continued declines in tequila brands including Don Julio. The company took a $287mn Impairment on its Don Papa rum Brand and additional charges relating to its Türkiye operations, part of $1.5bn in total impairments for the year. Group organic net sales fell 2.0%, with volumes down 0.4% — a volume decline that is notable in itself, since it indicates people are drinking less spirits by quantity, not merely trading down to cheaper brands. Sir Dave Lewis, appointed CEO on 1 January 2026, has pursued deep and rapid restructuring: full-time headcount fell from 29,860 to 27,938, a reduction of 1,922 roles, with $1bn of savings targeted over three years. Guinness, notably, delivered double-digit net sales growth in Great Britain over the same period — a beer brand thriving even as the group's core spirits categories struggled, a divergence that is central to understanding whether Diageo's problem is company-specific execution or category-wide demand erosion.
The Numbers
Independent industry data lends weight to the structural interpretation. EY-Parthenon consumer research from March 2025 found that 44% of GLP-1 medication users reported drinking less alcohol after starting the drugs, and that 82% of those who later stopped taking the medication maintained their reduced consumption levels — evidence that the effect on drinking habits may outlast the medication itself. Separately, industry data cited by EY shows that only around 50% of 18-to-34-year-olds in the United States reported drinking alcohol in 2025, down from roughly 60% two years earlier, a fall concentrated among younger, often more affluent consumers. Category growth data reinforces the divergence: low- and no-alcohol beverage sales in the US are projected to grow at a compound annual rate of roughly 13.6% between 2024 and 2029, versus approximately 2.1% CAGR for traditional alcohol categories over the same period, according to industry tracking cited by EY. Among consumers who report moderating their drinking, spirits saw a somewhat smaller share reducing consumption (40%) compared with wine (52%) and beer (43%), suggesting the pullback, while broad-based across categories, is not uniform. Against this backdrop, Diageo's own volume decline of 0.4% for the year — on top of unfavourable price/mix of 1.6 percentage points — sits consistently with an environment in which fewer people are drinking spirits at all, rather than simply an environment in which existing drinkers are temporarily buying less due to destocking.
Why It Matters
If the erosion in spirits demand is genuinely structural — driven by widening GLP-1 adoption, health-conscious moderation trends and generational shifts away from drinking — then cost-cutting, however well executed, addresses only the Supply side of Diageo's challenge. A $1bn savings programme improves margins and cash generation, and Lewis's swift action has already been rewarded by the market, but it does not by itself create new demand for the group's core tequila, whisky and vodka brands among consumers who are drinking less or not at all. This is precisely why Diageo's own strategic response extends beyond cost-cutting: the company is explicitly investing savings into Guinness production capacity and ready-to-drink canned cocktails — categories that have continued to grow even as neat spirits have not. Guinness's double-digit UK growth and the broader RTD cocktail trend both suggest that convenience, lower alcohol-by-volume formats, and beer retain appeal even among consumers who are moderating overall consumption, offering Diageo a plausible, if partial, hedge against structural spirits decline.
Investor & Market Perspective
The market's positive reaction to Diageo's results — shares rose 5.6% to £17.33, their highest level since February 2026 — reflects relief at decisive Leadership and improved free Cash Flow ($3.2bn, up $463mn) and Leverage (3.1 times net Debt to EBITDA, down from 3.4 times), rather than confidence that the top-line demand problem has been solved. Diageo's operating Margin before exceptional items expanded 116 basis points to 28.9% despite falling sales, demonstrating that cost discipline can support profitability even against a shrinking volume base — but margin expansion on a shrinking base has natural limits. Investors assessing Diageo's medium-term prospects should weigh the balance between its genuinely structural growth categories (Guinness, RTD cocktails, non-alcoholic and low-ABV extensions) against a spirits portfolio that, in the US at least, appears to be facing more than a normal cyclical adjustment. The GLP-1 effect in particular remains a live and expanding risk: employer health-plan coverage of weight-loss drugs has been expanding rapidly, with EY citing that 44% of large US employers already include such coverage, a figure likely to grow further and extend the base of consumers reporting reduced alcohol intake.
What Happens Next
Diageo's success in offsetting structural spirits softness will likely be measured by the growth trajectory of Guinness, RTD cocktails and any further category or brand-mix pivots Lewis announces, rather than by cost-savings delivery alone. Investors should watch for management commentary, expected at Diageo's first-half fiscal 2027 results around February 2027, on whether US spirits volumes have stabilised or continued to decline, and for any explicit acknowledgement from Lewis of GLP-1 and moderation trends as a lasting Factor in category planning, rather than a temporary headwind.
Outlook
Diageo's restructuring under Sir Dave Lewis is a necessary response to weak recent trading, but the deeper question facing the company is whether the world is simply drinking less spirits, for reasons unlikely to reverse — health-consciousness, GLP-1 medication and generational change chief among them. Cost cuts can restore near-term profitability; they cannot, on their own, restore demand for a category that a meaningful share of the next generation of consumers appears to be choosing more selectively, or not at all.




_11_18_2026_14_55_02_703826.jpg)

Please wait processing your request...